Immune cells can
help—or hurt.
A cancer treatment that removes certain immune cells might help some tumors but harm others.
What the study showsIn mice, removing CD4 immune cells slowed melanoma and kidney tumors but made liver tumors grow faster. The difference was linked to a tumor marker called MHC II. Researchers also found a related pattern in human cancer data, but this has not been tested as a way to choose patient treatment.
One study. A step toward better care.
Removing CD4 cells changed tumor growth in mice
MHC II helped explain the opposite effects
Study details & source
Using major histocompatibility complex (MHC) II expression to predict antitumor response to CD4+ lymphocyte depletion. Scientific Reports. 2025 Feb 14;15:5469. doi:10.1038/s41598-025-88972-8. Open full text.
Syngeneic mouse models included B16 melanoma, Renca kidney cancer, and Hepa1-6 liver cancer. CD4-depleting antibodies reduced tumor growth in B16 and Renca but increased growth in Hepa1-6. Experimentally altering tumor MHC II expression helped establish the mechanism. This is not a clinical trial.
Exploratory TCGA pan-cancer analysis found that higher CD4 expression correlated with better progression-free survival in tumors with high MHC II and low MHC I (p=0.0217); overall survival showed a nonsignificant trend (p=0.0770). These correlations do not demonstrate that depletion or preservation of CD4 cells improves patient outcomes.
Original two-panel schematic summarizes reported experimental directions without copying publisher artwork. Source: PMID 39953106 (Wang et al.); the article is distributed under CC BY-NC-ND 4.0.